Metabolic disorders in prediabetes:From mechanisms to therapeutic management  

作　　者：Wen-Xin Ping Shan Hu Jing-Qian Su Song-Ying Ouyang 

机构地区：[1]Biomedical Research Center of South China,College of Life Sciences,Fujian Normal University,Fuzhou 350117,Fujian Province,China

出　　处：《World Journal of Diabetes》2024年第3期361-377,共17页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by National Natural Science Foundation of China,No.31770948,No.31570875,and No.81803547;Natural Science Foundation of Fujian Province,No.2021J01204;and Fujian Provincial Regional Development Project,No.2021N3005.

摘　　要：Diabetes,one of the world's top ten diseases,is known for its high mortality and complication rates and low cure rate.Prediabetes precedes the onset of diabetes,during which effective treatment can reduce diabetes risk.Prediabetes risk factors include high-calorie and high-fat diets,sedentary lifestyles,and stress.Consequences may include considerable damage to vital organs,including the retina,liver,and kidneys.Interventions for treating prediabetes include a healthy lifestyle diet and pharmacological treatments.However,while these options are effective in the short term,they may fail due to the difficulty of long-term implementation.Medications may also be used to treat prediabetes.This review examines prediabetic treatments,particularly metformin,glucagon-like peptide-1 receptor agonists,sodium glucose cotransporter 2 inhibitors,vitamin D,and herbal medicines.Given the remarkable impact of prediabetes on the progression of diabetes mellitus,it is crucial to intervene promptly and effectively to regulate prediabetes.However,the current body of research on prediabetes is limited,and there is considerable confusion surrounding clinically relevant medications.This paper aims to provide a comprehensive summary of the pathogenesis of prediabetes mellitus and its associated therapeutic drugs.The ultimate goal is to facilitate the clinical utilization of medications and achieve efficient and timely control of diabetes mellitus.

关 键 词：PREDIABETES Glucagon-like peptide agonists Sodium–glucose cotransporter 2 inhibitors Vitamin D Chinese herbal medicines 

分 类 号：R587.1[医药卫生—内分泌]